We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Ranbaxy, Glaxo Bury Hatchet Over Valtrex

Law360 (July 26, 2007, 12:00 AM EDT) -- In a boost to Ranbaxy Laboratories Ltd., the Indian drug giant has won 180 days of exclusive rights to sell a generic version of GlaxoSmithKline's Valtrex in the United States after the two rivals settled a long-running patent dispute over the herpes treatment.

Ranbaxy said Thursday it had reached an agreement with Glaxo that had resulted in a dismissal of their U.S. litigation over Glaxo's U.S. Patent Number 4,957,924, which covers valacyclovir hydrochloride. In early February, Ranbaxy received a final approval from the U.S. Food and...
To view the full article, register now.